Predisposing factors endorsing Candida infections;Fattori predisponenti alle infezioni da Candida

Infezioni in Medicina

Volumn 23, Issue 3, 2015, Pages 211-223

  Singh, Shweta ^a   Fatima, Zeeshan ^a   Hameed, Saif ^a  

^a AMITY UNIVERSITY HARYANA   (India)

Author keywords

AIDS; Burn; Candida albicans; Immunocompromised; MDR; Organ transplant

Indexed keywords

ASPARTIC PROTEINASE; CASPOFUNGIN; GELATINASE A; GELATINASE B; HISTATIN 5; INTERLEUKIN 17; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 3; PROSTAGLANDIN E2; SECRETED ASPARTYL PROTEINASE 2; STAT3 PROTEIN; STROMELYSIN; THROMBOSPONDIN 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UVOMORULIN; VORICONAZOLE; ANTIFUNGAL AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BREAST CANCER; BURN; CANDIDA ALBICANS; CANDIDA FAMATA; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA SAKE; CANDIDA TROPICALIS; CANDIDIASIS; CATHETER; CLOSTRIDIUM DIFFICILE INFECTION; DIABETES MELLITUS; DISEASE PREDISPOSITION; GENE MUTATION; GENETIC SUSCEPTIBILITY; HOSPITAL INFECTION; IMMUNE RESPONSE; KIDNEY GRAFT; KLEBSIELLA PNEUMONIAE INFECTION; LIVER TRANSPLANTATION; MEYEROZYMA GUILLIERMONDII; NATURAL KILLER CELL; PICHIA KUDRIAVZEVII; PREGNANCY; PROTEIN EXPRESSION; REVIEW; SEPSIS; WICKERHAMOMYCES ANOMALUS; COMPLICATION; CROSS INFECTION; HUMAN; IMMUNOCOMPROMISED PATIENT; ITALY; MICROBIOLOGY; PATHOGENICITY; RISK FACTOR;

ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CANDIDIASIS; CROSS INFECTION; HUMANS; IMMUNOCOMPROMISED HOST; ITALY; RISK FACTORS;

EID: 84943252734     PISSN: 11249390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (90)

1. Hameed S., Fatima Z. Novel regulatory mechanisms of pathogenicity and virulence to combat MDR in Candida albicans. Int. J. Microbiol. 240209, 1-10, 2013.
2. Das I., Nightingale P., Patel M., Jumaa P. Epidemiology, clinical characteristics, and outcome of candidemia: experience in a tertiary referral center in the UK. Int. J. Infect. Dis. 15, 759-763, 2011.
3. Tanwar J., Das S., Fatima Z., Hameed S. Crusade for opportunity: Candida albicans from commensalism to pathogenicity. J. Hum. Dis. 112, 160-167, 2013.
4. Tanwar J., Das S., Fatima Z., Hameed S. Multidrug resistance: an emerging crisis. Interdiscip. Perspect. Infect. Dis. 541340, 1-7, 2014.
5. Reed B.D. Risk factors for Candida vulvovaginitis. Obstet. Gynecol. Surv. 47, 551-560, 1992.
6. Samaranayake L.P. Oral mycoses in HIV infection. Oral Surg. Oral Med. Oral Pathol. 73, 171-180, 1992.
7. Sharifzadeh A., Khosravi A.R., Shokri H., Asadi Jamnani F., Hajiabdolbaghi M., Ashrafi Tamami I. Oral microflora and their relation to risk factors in HIV+ patients with oropharyngeal candidiasis. J. Mycol. Med. 23, 105-112, 2013.
8. Demiraslan H., Alabay S., Kilic A.U., Borlu M., Doganay M. Cutaneous candidiasis caused by Candida glabrata in a HIV/AIDS patient. Int. J. STD. AIDS 24, 753-755, 2013.
9. Hernandez-Solis S.E., Rueda-Gordillo F., Rojas- Herrera R.A. Proteinase activity in Candida albicans strains isolated from the oral cavity of immunocompromised patients, with oral candidiasis and in healthy subjects. Rev. Iberoam. Micol. 31, 137-140, 2014.
10. Li S.S., Kyei S.K., Timm-McCann M. et al. The NK receptor NKp30 mediates direct fungal recognition and killing and is diminished in NK cells from HIVinfected patients. Cell Host Microbe 14, 387-397, 2013.
11. Kwamin F., Nartey N.O., Codjoe F.S., Newman M.J. Distribution of Candida species among HIV-positive patients with oropharyngeal candidiasis in Accra, Ghana. J. Infect. Dev. Ctries 7, 41-45, 2013.
12. Cassone A., Cauda R. Candida and candidiasis in HIV-infected patients: where commensalism, opportunistic behavior and frank pathogenicity lose their borders. AIDS 26, 1457-1472, 2012.
13. Rodriguez Rodrigues C., Remes Lenicov F., Jancic C. et al. Candida albicans delays HIV-1 replication in macrophages. PLoS One 8, e72814, 2013.
14. Esebelahie N.O., Enweani I.B., Omoregie R. Candida colonisation in asymptomatic HIV patients attending a tertiary hospital in Benin City, Nigeria. Libyan J. Med. 18, 1-5, 2013.
15. Santos A.L., Braga-Silva L.A. Aspartic protease inhibitors: effective drugs against the human fungal pathogen Candida albicans. Mini. Rev. Med. Chem. 13, 155-162, 2013.
16. da Silva W.J., Goncalves L.M., Seneviratne J., Parahitiyawa N., Samaranayake L.P., Del Bel Cury A.A. Exopolysaccharide matrix of developed Candida albicans biofilms after exposure to antifungal agents. Braz. Dent. J. 23, 716-722, 2012.
17. Yang C.H., He X.S., Chen J., et al. Fungal infection in patients after liver transplantation in years 2003 to 2012. Ann. Transplant. 17, 59-63, 2012.
18. Gupta K.L., Ghosh A.K., Kochhar R., Jha V., Chakrabarti A., Sakhuja V. Esophageal candidiasis after renal transplantation: comparative study in patients on different immunosuppressive protocols. Am. J. Gastroenterol. 89, 1062-1065, 1994.
19. Lopez-Pintor R.M., Hernandez G., de Arriba L., de Andres A. Oral candidiasis in patients with renal transplants. Med. Oral. Patol. Oral. Cir. Bucal. 18, 381- 387, 2013.
20. Solla-Buceta M., Hurtado-Doce A., Alvarez-Rocha L. Persistent candidemia in a renal-pancreatic transplant patient. Rev. Iberoam. Micol. 29, 76-80, 2012.
21. da Silva-Rocha W.P., de Brito Lemos V.L., Svidizisnki T.I.E., Milan E.P., Chaves G.M. Candida species distribution, genotyping and virulence factors of Candida albicans isolated from the oral cavity of kidney transplant recipients of two geographic regions of Brazil. BMC. Oral. Health. 14, 1-9, 2014.
22. Sganga G., Bianco G., Frongillo F., Lirosi M.C., Nure E., Agnes S. Fungal infections after liver transplantation: incidence and outcome. Transplant. Proc. 46, 2314-2318, 2014.
23. Routh M.M., Chauhan N.M., Karuppayil S.M. Cancer drugs inhibit morphogenesis in the human fungal pathogen, Candida albicans. Braz. J. Microbiol. 44, 855-859, 2013.
24. Kliasova G.A., Blokhina E.V., Gracheva A.N., Kravchenko S.K., Parovichnikova E.N., Galstian G.M. Results of treatment for candidemia in patients with blood system tumors. Ter. Arkh. 85, 47-53, 2013.
25. Koziol-Montewka M., Magrys A., Paluch-Oles J., Bogut A., Buczynski K., Jablonka S. MPO and cytokines in the serum of cancer patients in the context of Candida colonization and infection. Immunol. Invest. 35, 167-179, 2006.
26. Taheri F.H., Seyedolmohadesin M., Bayat M., et al. The Effect of Candida albicans systemic infection on matrix metalloproteinases in breast cancer bearing BALB/c mice. Iran. J. Allergy Asthma Immunol. 12, 81- 85, 2013.
27. Deva R., Sczepanski M., Saha S., et al. Candida albicans activates cyclooxygenase but not its product prostaglandin E2 in HPV 16-stabilized cells. Eur. J. Obstet. Gynecol. Reprod. Biol. 152, 205-209, 2010.
28. Bar E., Whitney P.G., Moor K., Reis e Sousa C., Leibund Gut-Landmann S. IL-17 regulates systemic fungal immunity by controlling the functional competence of NK cells. Immunity 40, 117-127, 2014.
29. Martin-Manso G., Dhammika H.M., Navarathna L.M., et al. Endogenous Thrombospondin-1 regulates leukocyte recruitment and activation and accelerates death from systemic candidiasis. PLoS One 7, e48775, 2012.
30. Wang Y., Gao X., Zhi Gang J.U., Liu J., Dong S., Wang L. Detection of Candida albicans Sap2 in cancer patient serum samples by an indirect competitive enzyme- linked immunosorbent assay for the diagnosis of candidiasis. Indian J. Pathol. Microbiol. 56, 243-247, 2013.
31. Fidan I., Yesilyurt E., Kalkanci A. et al. Immunomodulatory effects of voriconazole and caspofungin on human peripheral blood mononuclear cells stimulated by Candida albicans and Candida krusei. Am. J. Med. Sci. 348, 219-223, 2014.
32. Costa-de-Oliveira S., Sousa I., Correia A., et al. Genetic relatedness and antifungal susceptibility profile of Candida albicans isolates from fungaemia patients. Med. Mycol. 49, 248-252, 2011.
33. Holland S.M., DeLeo F.R., Elloumi H.Z., et al. STAT3 mutations in the hyper-IgE syndrome. N. Engl. J. Med. 357, 1608-1619, 2007.
34. de Beaucoudrey L., Puel A., Filipe-Santos O., et al. Mutations in STAT3 and IL12RB1 impair the development of human IL-17-producing T cells. J. Exp. Med. 205, 1543-1550, 2008.
35. Ouederni M., Sanal O., Ikinciogullari A., et al. Clinical features of candidiasis in patients with interleukin- 12 receptor B1 deficiency. Clin. Infect. Dis. 58, 204-213, 2012.
36. Plantinga T.S., Johnson M.D., Scott W.K., et al. Toll-like receptor polymorphisms increase susceptibility to candidemia. J. Infect. Dis. 205, 934-943, 2012.
37. Rosentul D.C., Plantinga T.S., Oosting M., et al. Genetic variation in the dectin-1/CARD9 recognition pathway and susceptibility to candidemia. J. Infect. Dis. 204, 1138-1145, 2011.
38. Jordan I., Hernandez L., Balaguer M. C. albicans, C. parapsilosis and C. tropicalis invasive infections in the PICU: clinical features, prognosis and mortality. Rev. Esp. Quimioter. 27, 56-62, 2014.
39. Arendrup M.C. Epidemiology of invasive candidiasis. Curr. Opin. Crit. Care 16, 445-452, 2010.
40. Chakrabarti A., Sood P., Rudramurthy S.M., et al. Incidence, characteristics and outcome of ICUacquired candidemia in India. Intensive Care Med. 41, 285-295, 2015.
41. Kapoor G., Saigal S., Saigal K. Why candidemia occurs early: a comment on "incidence, characteristics and outcome of ICU-acquired candidemia in India". Intensive Care Med. 41, 377, 2015.
42. Martins N., Isabel C. F., Ferreira R., Silva S., Henriques M. Candidiasis: predisposing factors, prevention, diagnosis and alternative treatment. Mycopathologia 177, 223-240, 2014.
43. Erdem F., Tuncer Ertem G., Oral B., Karakoc E., Demiroz A.P., Tulek N. Epidemiological and microbiological evaluation of nosocomial infections caused by Candida species. Mikrobiyol. Bul. 46, 637-648, 2012.
44. Chapman R.L. Candida infections in the neonate. Curr. Opin. Pediatr. 15, 97-102, 2003.
45. Tiraboschi I.N., Carnovale S., Benetucci A., et al. Candida albicans outbreak in a neonatal intensive care unit. Rev. Iberoam. Micol. 24, 263-267, 2007.
46. Yu Y., Du L., Yuan T., et al. Risk factors and clinical analysis for invasive fungal infection in neonatal intensive care unit patients. Am. J. Perinatol. 30, 589- 594, 2013.
47. Hammoud M.S., Al-Taiar A., Fouad M., Raina A., Khan Z. Persistent candidemia in neonatal care units: risk factors and clinical significance. Int. J. Infect. Dis. 17, 624-628, 2013.
48. Cat T.B., Charash W., Hebert J., et al. Potential influence of antisecretory therapy on the development of Candida-associated intraabdominal infection. Ann. Pharmacother. 42, 185-191, 2008.
49. Pasqualotto A.C., Nedel W.L., Machado T.S., Severo L.C. A comparative study of risk factors and outcome among outpatient-acquired and nosocomial Candidaemia. J. Hosp. Infect. 60,129-134, 2005.
50. De Rosa F.G., Trecarichi E.M., Montrucchio C. et al. Mortality in patients with early- or late-onset candidaemia. J. Antimicrob. Chemother. 68, 927-935, 2013.
51. Mean M., Marchetti O., Calandra T. Bench-to-bedside review: Candida infections in the intensive care unit. Crit. Care 12, 1-9, 2008.
52. Douglas L.J. Candida biofilms and their role in infection. TRENDS in Microbiology. 11, 30-36, 2003.
53. Ramage G., Martinez J.P., Lopez-Ribot J.L. Candida biofilms on implanted biomaterials: a clinically significant problem, FEMS Yeast Res. 6, 979-986, 2006.
54. Chandra J., Kuhn D.M., Mukherjee P.K., Hoyer L.L., Mccormick T., Mahmoud A. Biofilm formation by the fungal pathogen Candida albicans: development, architecture, and drug resistance. J. Bacteriol. 183, 5385-5394, 2001.
55. Russo A., Falcone M., Fantoni M. Risk factors and clinical outcomes of candidaemia in patients treated for Clostridium difficile infection. Clin. Microbiol. Infect. 21, 5, 493, e1-e4, 2015.
56. De Rosa F.G., Corcione S., Pagani N., Di Perri G. From ESKAPE to ESCAPE, From KPC to CCC. Clin. Infect. Dis. 60, 1289-1290, 2015.
57. Papadimitriou-Olivgeris M., Spiliopoulou A., Fligou F. Association of KPC-producing Klebsiella pneumoniae colonization or infection with Candida isolation and selection of non-albicans species. Diagn. Microbiol. Infect. Dis. 80, 227-232, 2014.
58. Agvald-Ohman C., Klingspor L., Hjelmqvist H., Edlund C. Invasive candidiasis in long-term patients at a multidisciplinary intensive care unit: Candida colonization index, risk factors, treatment and outcome. Scand. J. Infect. Dis. 40, 145-153, 2008.
59. Bassetti M., Marchetti M., Chakrabarti A. A research agenda on the management of intra-abdominal candidiasis: results from a consensus of multinational experts. Intensive Care Med. 39, 2092-2106, 2013.
60. Fisher B.M., Lamey P.J., Samaranayake L.P., MacFarlane T.W., Frier B.M. Carriage of Candida species in the oral cavity in diabetic patients: relationship to glycaemic control. J. Oral. Pathol. 16, 282-284, 1987.
61. Wild S., Roglic G., Green A., Sicree R., King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27, 1047- 1053, 2004.
62. Martinez R.F., Jaimes-Aveldanez A., Hernandez- Perez F., Arenas R., Miguel G.F. Oral Candida spp carriers: its prevalence in patients with type 2 diabetes mellitus. An. Bras. Dermatol. 88, 222-225, 2013.
63. Pallavan B., Ramesh V., Dhanasekaran B.P., Oza N., Indu S., Govindarajan V. Comparison and correlation of candidal colonization in diabetic patients and normal individuals. J. Diabetes. Metab. Disord. 13, 1-6, 2014.
64. Soysa N.S., Samaranayake L.P., Ellepola A.N. Diabetes mellitus as a contributory factor in oral candidosis. Diabet. Med. 23, 455-459, 2006.
65. Al-Attas S.A., Amro S.O. candidal colonization, strain diversity, and antifungal susceptibility among adult diabetic patients. Ann. Saudi. Med. 30, 101-108, 2010.
66. Yildirim Z., Kilic N., Kalkanci A. Fluorometric determination of acid proteinase activity in Candida albicans strains from diabetic patients with vulvovaginal candidiasis. Mycoses 54, 463-467, 2011.
67. Geerlings S.E., Hoepelman A.I. Immune dysfunction in patients with diabetes mellitus (DM). FEMS. Immunol. Med. Microbiol. 26, 259-265, 1999.
68. Willis A.M., Coulter W.A., Fulton C.R., Hayes J.R., Bell P.M., Lamey P.J. The influence of antifungal drugs on virulence properties of Candida albicans in patients with diabetes mellitus. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 91, 317-321, 2001.
69. Chen S.C., Playford E.G., Sorrell T.C. Antifungal therapy in invasive fungal infections. Curr. Opin. Pharmacol. 10, 522-530, 2010.
70. Luo G., Peng Y., Yuan Z., Cheng W., Wu J., Fitzgerald M. Yeast from burn patients at a major burn centre of China. Burns 37, 299-303, 2011.
71. Pruitt B.A., McManus A.T. Kim S.H., Goodwin C.W. Burn wound infections: current status. World. J. Surg. 22, 135-145, 1998.
72. Macherla C., Sanchez D.A., Ahmadi M.S., et al. Nitric oxide releasing nanoparticles for treatment of Candida albicans burn infections. Front. Microbiol. 8, 193, 2012.
73. Capoor M.R., Gupta S., Sarabahi S., Mishra A., Tiwari V.K., Aggarwal P. Epidemiological and clinicomycological profile of fungal wound infection from largest burn centre in Asia. Mycoses 55, 181-188, 2012.
74. Kobayashi M., Kobayashi H., Herndon D.N., Pollard R.B., Suzuki F. Burn-associated Candida albicans infection caused by CD301 type 2 T cells. J. Leukoc. Biol. 63,723-731, 1998.
75. Shupp J.W., Petraitiene R., Jaskille A.D., et al. Early serum (1E3)-3-D-glucan levels in patients with burn injury. Mycoses 55, 224-227, 2012.
76. Barton M., O'Brien K., Robinson J.L., et al. Invasive candidiasis in low birth weight preterm infants: risk factors, clinical course and outcome in a prospective multicenter study of cases and their matched controls. BMC Infect. Dis.14, 327, 2014.
77. Filippidi A., Galanakis E., Maraki S., et al. The effect of maternal flora on Candida colonisation in the neonate. Mycoses 57, 43-48, 2014.
78. Sharma S., Gangwal K. Neonatal Candida arthritis. Indian J. Orthop. 48, 339-342, 2014.
79. Panahi Y., Sharif M.R., Sharif A., et al. A randomized comparative trial on the therapeutic efficacy of topical aloe vera and Calendula officinalis on diaper dermatitis in children. Scientific World Journal 810234, 1-5, 2012.
80. Wolf R., Wolf D., Tuzun B., Tuzun Y. Diaper dermatitis. Clin. Dermatol. 18, 657-660, 2012.
81. Leli C., Mencacci A., Meucci M. Association of pregnancy and Candida vaginal colonization in women with or without symptoms of vulvovaginitis. Minerva Ginecol. 65, 303-309, 2013.
82. Ibrahim S.M., Bukar M., Mohammed Y., Audu B.M., Ibrahim H.M. Prevalence of vaginal candidiasis among pregnant women with abnormal vaginal discharge in Maiduguri. Niger. J. Med. 22, 138-142, 2013.
83. Namkinga L.A., Matee M.I., Kivaisi A.K. Identification of Candida strains isolated from Tanzanian pregnant women with vaginal candidiasis. East. Afr. Med. J. 82, 226-234, 2005.
84. Zheng N.N., Guo X.C., Lv W., Chen X.X., Feng G.F. Characterization of the vaginal fungal flora in pregnant diabetic women by 18S rRNA sequencing. Eur. J. Clin. Microbiol. Infect. Dis. 32, 1031-1040, 2013.
85. Kalkanci A., Guzel A.B., Khalil I.I., Aydin M., Ilkit M., Kustimur S. Yeast vaginitis during pregnancy: susceptibility testing of 13 antifungal drugs and boric acid and the detection of four virulence factors. Med. Mycol. 50, 585-593, 2012.
86. Nikolov A., Shopova E., Mikhova M., Dimitrov A. Treatment in cases of recurrent vaginal Candida infection during pregnancy. Akush. Ginekol. (Sofiia). 46, 23-26, 2007.
87. Garcia Heredia M., Garcia S.D., Copolillo E.F., et al. Prevalence of vaginal candidiasis in pregnant women. Identification of yeasts and susceptibility to antifungal agents. Rev. Argent. Microbiol. 38, 9-12, 2006.
88. Rubinstein E., Mark Z., Haspel J., et al. Antibacterial activity of the pancreatic fluid. Gastroenterology 88, 927-932, 1998.
89. Abe F., Nagata S., Hotchi M. Experimental candidiasis in liver injury. Mycopathologia 100, 37-42, 1987.
90. G. Garcia-Elorriaga, G. del Rey-pineda G. Nutrition and intestinal microflora. J. Nutr. Ther. 2, 112-121, 2013.